top of page
Search
  • katrina4384

Sage Therapeutics Announces Topline Results from the Phase 2 SURVEYOR Study.



"The study met its primary endpoint, demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD_CAB) composite score at baseline between healthy participants with Huntington's Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo."


192 views0 comments

Comentarios


bottom of page